000086276 001__ 86276
000086276 005__ 20200609132536.0
000086276 0247_ $$2doi$$a10.1111/ane.13059
000086276 0248_ $$2sideral$$a109799
000086276 037__ $$aART-2018-109799
000086276 041__ $$aeng
000086276 100__ $$aVillanueva, V.
000086276 245__ $$aBRIVA-LIFE–A multicenter retrospective study of the long-term use of brivaracetam in clinical practice
000086276 260__ $$c2018
000086276 5060_ $$aAccess copy available to the general public$$fUnrestricted
000086276 5203_ $$aObjectives: Evaluate long-term effectiveness and tolerability of brivaracetam in clinical practice in patients with focal epilepsy.
Materials and Methods: This was a multicenter retrospective study. Patients aged =16 years were started on brivaracetam from November 2016 to June 2017 and followed over 1 year. Data were obtained from medical records at 3, 6 and 12 months after treatment initiation for evaluation of safety- and seizure-related outcomes.
Results: A total of 575 patients were included in analyses; most had been treated with =4 lifetime antiepileptic drugs. Target dosage was achieved by 30.6% of patients on the first day. Analysis of primary variables at 12 months revealed that mean reduction in seizure frequency was 36.0%, 39.7% of patients were =50% responders and 17.5% were seizure-free. Seizure-freedom was achieved by 37.5% of patients aged =65 years. Incidence of adverse events (AEs) and psychiatric AEs (PAEs) was 39.8% and 14.3%, respectively, and discontinuation due to these was 8.9% and 3.7%, respectively. Somnolence, irritability, and dizziness were the most frequently reported AEs. At baseline, 228 (39.7%) patients were being treated with levetiracetam; most switched to brivaracetam (dose ratio 1:10-15). Among those who switched because of PAEs (n = 53), 9 (17%) reported PAEs on brivaracetam, and 3 (5.7%) discontinued because of PAEs. Tolerability was not highly affected among patients with learning disability or psychiatric comorbidity.
Conclusions: In a large population of patients with predominantly drug-resistant epilepsy, brivaracetam was effective and well-tolerated; no unexpected AEs occurred over 1 year, and the incidence of PAEs was lower compared with levetiracetam.
000086276 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000086276 590__ $$a2.852$$b2018
000086276 591__ $$aCLINICAL NEUROLOGY$$b86 / 199 = 0.432$$c2018$$dQ2$$eT2
000086276 592__ $$a1.225$$b2018
000086276 593__ $$aMedicine (miscellaneous)$$c2018$$dQ1
000086276 593__ $$aNeurology (clinical)$$c2018$$dQ1
000086276 593__ $$aNeurology$$c2018$$dQ1
000086276 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/submittedVersion
000086276 700__ $$aLópez-González, F.J.
000086276 700__ $$0(orcid)0000-0001-8530-0616$$aMauri, J.A.$$uUniversidad de Zaragoza
000086276 700__ $$aRodriguez-Uranga, J.
000086276 700__ $$aOlivé-Gadea, M.
000086276 700__ $$aMontoya, J.
000086276 700__ $$aRuiz-Giménez, J.
000086276 700__ $$aZurita, J.
000086276 700__ $$aAbril, J.
000086276 700__ $$aToledo, M.
000086276 700__ $$aGarcés, M.
000086276 700__ $$aGómez-Ibáñez, A.
000086276 700__ $$aHampel, K.
000086276 700__ $$aRodriguez-Osorio, X.
000086276 700__ $$aPoza, J.J.
000086276 700__ $$aCampos, D.
000086276 700__ $$aOjeda, J.
000086276 700__ $$aTortosa, D.
000086276 700__ $$aCastro-Vilanova, M.D.
000086276 700__ $$aSaiz-Diaz, R.
000086276 700__ $$aGonzález de la Aleja, J.
000086276 700__ $$aCastillo, A.
000086276 700__ $$ade Toledo, M.
000086276 700__ $$aGago-Veiga, A.B.
000086276 700__ $$aPiera, A.
000086276 700__ $$aCrisostomo, J.
000086276 700__ $$afor, the, BRIVA-LIFE, study, group
000086276 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000086276 773__ $$g139, 4 (2018), 360 - 368$$pActa neurol. Scand.$$tACTA NEUROLOGICA SCANDINAVICA$$x0001-6314
000086276 8564_ $$s827564$$uhttps://zaguan.unizar.es/record/86276/files/texto_completo.pdf$$yPreprint
000086276 8564_ $$s214287$$uhttps://zaguan.unizar.es/record/86276/files/texto_completo.jpg?subformat=icon$$xicon$$yPreprint
000086276 909CO $$ooai:zaguan.unizar.es:86276$$particulos$$pdriver
000086276 951__ $$a2020-06-09-13:23:09
000086276 980__ $$aARTICLE